Global Bovine high-mountain disease demand is projected to be valued at US$ 4.32 Billion in 2022, forecast to grow at a CAGR of 5.25% to be valued at US$ 7.2 Billion from 2022 to 2032. Growth is attributed to the rising demand for renovation projects and development in residential and commercial construction.
| Report Attribute | Details |
| Estimated Base Year Value (2021) | US$ 4.1 Billion |
| Expected Market Value (2022) | US$ 4.32 Billion |
| Anticipated Forecast Value (2032) | US$ 7.2 Billion |
| Projected Growth Rate (2022-2032) | 5.25% CAGR |
Bovine high-mountain disease (BHMD) is also known as brisket disease which causes significant death loss, especially in calves. The bovine high-mountain disease is right heart failure which is generally caused due to hypoxic pulmonary hypertension at high altitudes. The bovine high-mountain disease is found in cattle at elevations over 7,000 feet and affects cattle of all ages and breeds.
Higher elevations directly increase the incidence rate of bovine respiratory disease. The bovine high-mountain disease is generally associated with factors like altitude, physiologic, genetic, and environmental. It is also said that bovine high-mountain disease could be associated with mortality and morbidity associated with bovine respiratory disease (BRD). Some of the symptoms associated with the bovine high-mountain disease are weakness, collapse, diarrhea, bulging eyes, swelling due to edema of the limbs, and others.
The rising incidence of congestive heart failure in cattle is considered a major driving factor in driving the growth of the global bovine high-mountain disease market. Furthermore, the rising prevalence of respiratory disease, lung abscesses, migrating parasitic larvae and lungworms, and genetic susceptibility further contribute to boosting the growth of the global bovine high-mountain disease drug market.
A susceptible animal is generally more prone to develop bovine high-mountain disease if any of the above parameters are present.
There are also other diseases (like congenital heart disease, parasites, etc.) that are very similar to the bovine high-mountain disease which often causes difficulties in differentiating them. Thus, the lack of information about the bovine high-mountain disease is expected to hamper the growth of the global bovine high-mountain disease market.
Generally, a pulmonary artery pressure (PAP) test is conducted in order to determine the bovine high-mountain disease. The high cost related to the treatment of bovine high-mountain disease is also expected to deter the growth of the global bovine high-mountain disease market.
APAC region has witnessed a tremendous increment in the bovine high-mountain disease in the past 2 to 3 decades. Numerous range plants, both browse and non-browse types, have been linked with augmented incidence of BHMD, but only locoweed has been experimentally shown to induce the disease.
Moreover, owing to poor health facilities in the hilly areas, the cattle are unable to get proper treatment and oxygen support due to high altitude. Governments of several countries are setting up veterinary hospitals in hilly residential areas to provide quick medical support, thereby, fostering the bovine high-mountain disease drug market.
Western Europe is anticipated to register the second most market share in the global bovine high-mountain disease market due to the presence of established manufacturers in the region. The Latin American bovine high-mountain disease market is expected to grow at a significant growth rate over the forecast period.
North American bovine high-mountain disease market is anticipated to register a maximum market share in the global bovine high-mountain disease market. The bovine high-mountain disease is very common in cattle raised on ranches at high altitudes (more than 5,000 feet) in Colorado, Wyoming, New Mexico, and Utah. It also affects cattle in mountainous ranges of the world, most commonly at elevations >6,500 ft (1,981 m) in western Canada and South America. BHMD affects cattle of all ages and breeds, but not necessarily equally.
Some of the key participants present in the global demand of the Bovine high-mountain disease market include Zoetis, Inc., Bayer AG, Eli Lilly and Company (Elanco), Dechra Pharmaceuticals, Merck & Co., Inc, and others.
| Report Attribute | Details |
| Growth Rate | CAGR of 5.25% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2016-2021 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons, and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Drug Class:
By Distribution Channel:
By Region:
FMI projects the global demand of the bovine high-mountain disease market to expand at a 5.25% value CAGR by 2032
Which region is forecast to be the most lucrative for bovine high-mountain disease market growth?
Zoetis, Inc., Bayer AG, Eli Lilly and Company (Elanco), Dechra Pharmaceuticals, Merck & Co., Inc, and others.
Explore Similar Insights
Bovine High-Mountain Disease Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
